[go: up one dir, main page]

CY1124753T1 - Συνθεση ενωσεων βορονικων εστερων και οξεων - Google Patents

Συνθεση ενωσεων βορονικων εστερων και οξεων

Info

Publication number
CY1124753T1
CY1124753T1 CY20211101021T CY211101021T CY1124753T1 CY 1124753 T1 CY1124753 T1 CY 1124753T1 CY 20211101021 T CY20211101021 T CY 20211101021T CY 211101021 T CY211101021 T CY 211101021T CY 1124753 T1 CY1124753 T1 CY 1124753T1
Authority
CY
Cyprus
Prior art keywords
composition
boronic esters
acids compounds
boronic
acids
Prior art date
Application number
CY20211101021T
Other languages
English (en)
Inventor
I. Fraser Pickersgill
John Bishop
Young Lo
Fang-Ting Chui
Vithalanand R. Kulkarni
Original Assignee
Millennium Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34968044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124753(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals, Inc. filed Critical Millennium Pharmaceuticals, Inc.
Publication of CY1124753T1 publication Critical patent/CY1124753T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)

Abstract

Η εφεύρεση σχετίζεται με την σύνθεση ενώσεων βορονικών εστέρων και οξέων. Περισσότερο δε ειδικότερα, η εφεύρεση παρέχει βελτιωμένες συνθετικές διεργασίες για την παραγωγή μεγάλης κλίμακας ενώσεων βορονικών εστέρων και οξέων που συμπεριλαμβάνουν τον αναστολέα πρωτεασωματίων βορονικού οξέος πεπτιδίων βορτεζομίμπη.
CY20211101021T 2004-03-30 2021-11-24 Συνθεση ενωσεων βορονικων εστερων και οξεων CY1124753T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55753504P 2004-03-30 2004-03-30
EP11167263A EP2377868A1 (en) 2004-03-30 2005-03-24 Synthesis of Bortezomib
PCT/US2005/009774 WO2005097809A2 (en) 2004-03-30 2005-03-24 Synthesis of boronic ester and acid compounds
EP05742865A EP1756121B1 (en) 2004-03-30 2005-03-24 Synthesis of boronic ester and acid compounds

Publications (1)

Publication Number Publication Date
CY1124753T1 true CY1124753T1 (el) 2022-07-22

Family

ID=34968044

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20111101122T CY1112053T1 (el) 2004-03-30 2011-11-21 Συνθεση ενωσεων βορονικων εστερων και οξεων
CY20141100297T CY1115336T1 (el) 2004-03-30 2014-04-17 Συνθεση της βορτεζομιμπης
CY20211101021T CY1124753T1 (el) 2004-03-30 2021-11-24 Συνθεση ενωσεων βορονικων εστερων και οξεων

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20111101122T CY1112053T1 (el) 2004-03-30 2011-11-21 Συνθεση ενωσεων βορονικων εστερων και οξεων
CY20141100297T CY1115336T1 (el) 2004-03-30 2014-04-17 Συνθεση της βορτεζομιμπης

Country Status (41)

Country Link
US (14) US7714159B2 (el)
EP (5) EP1756121B1 (el)
JP (4) JP4558039B2 (el)
KR (1) KR100939598B1 (el)
CN (5) CN108329337B (el)
AR (3) AR049374A1 (el)
AT (1) ATE521612T1 (el)
AU (1) AU2005230930B2 (el)
BR (1) BRPI0509587A (el)
CA (4) CA2560886C (el)
CL (2) CL2010000350A1 (el)
CR (1) CR8653A (el)
CY (3) CY1112053T1 (el)
DK (4) DK4008721T3 (el)
DO (1) DOP2011000293A (el)
EA (1) EA012927B1 (el)
EC (1) ECSP066960A (el)
ES (4) ES2974758T3 (el)
FI (1) FI4008721T3 (el)
HK (4) HK1100004A1 (el)
HR (4) HRP20240307T3 (el)
HU (2) HUE056859T2 (el)
IL (3) IL178250A (el)
LT (2) LT4008721T (el)
ME (1) ME01975B (el)
MX (1) MX367324B (el)
MY (1) MY145427A (el)
NL (3) NL1028639C2 (el)
NO (4) NO338905B1 (el)
NZ (3) NZ550522A (el)
PE (3) PE20060162A1 (el)
PL (4) PL4008721T3 (el)
PT (4) PT1756121E (el)
RS (4) RS62738B1 (el)
SG (5) SG10201600029PA (el)
SI (4) SI4008721T1 (el)
TW (1) TWI386212B (el)
UA (1) UA90108C2 (el)
UY (3) UY28830A1 (el)
WO (1) WO2005097809A2 (el)
ZA (1) ZA200608689B (el)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
ES2974758T3 (es) 2004-03-30 2024-07-01 Millennium Pharm Inc Síntesis de compuestos de ésteres y ácidos borónicos
WO2008075376A1 (en) * 2006-12-18 2008-06-26 Natco Pharma Limited Polymorphic forms of bortezomib and process for their preparation
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
KR20160040735A (ko) * 2007-08-06 2016-04-14 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
WO2009026579A1 (en) * 2007-08-23 2009-02-26 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
BRPI0816807A2 (pt) * 2007-09-12 2017-05-16 Dr Reddy's Laboratories Inc bortezomib e processo para a produção do mesmo
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EP2318419B2 (en) 2008-06-17 2024-10-30 Takeda Pharmaceutical Company Limited Boronate ester compounds and pharmaceutical compositions thereof
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AU2013204881A1 (en) * 2008-09-29 2013-05-16 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
CN101899062B (zh) * 2009-05-26 2015-04-15 上海威智医药科技有限公司 α-手性硼酸及硼酸酯的合成工艺
EP2280016A1 (en) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
WO2010146176A2 (en) 2009-06-19 2010-12-23 Lek Pharmaceuticals D.D. Process for hydrogenation of halogenoalkenes without dehalogenation
EP2270019A1 (en) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
CA2785300A1 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
CA2789400A1 (en) 2010-02-09 2011-08-18 Ranbaxy Laboratories Limited Process for the preparation of bortezomib
CN101781326B (zh) * 2010-02-11 2013-08-21 福建南方制药股份有限公司 一种制备手性氨基硼酸的中间体及其制备方法
WO2011107912A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Polymorphic forms of bortezomib
AU2011227083B2 (en) * 2010-03-18 2013-07-18 Innopharma, Inc. Stable bortezomib formulations
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
CN102892291A (zh) 2010-03-31 2013-01-23 米伦纽姆医药公司 1-氨基-2-环丙基乙硼酸衍生物
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
MX2012013100A (es) 2010-05-18 2013-01-22 Cerulean Pharma Inc Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
WO2012048745A1 (en) 2010-10-14 2012-04-19 Synthon Bv Process for making bortezomib and intermediates for the process
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
CN102206188B (zh) * 2011-04-08 2013-02-27 苏州二叶制药有限公司 N-(吡嗪-2-基羰基)-l-苯丙氨酸的制备方法
US8497374B2 (en) 2011-05-12 2013-07-30 Scinopharm Taiwan, Ltd. Process for preparing and purifying bortezomib
CN102268029B (zh) * 2011-05-19 2013-10-09 苏州二叶制药有限公司 化合物（1s,2s,3r,5s）-蒎烷二醇-l-苯丙氨酸-l-亮氨酸硼酸酯的制备
WO2012177835A1 (en) 2011-06-22 2012-12-27 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
CN102351890B (zh) * 2011-09-30 2014-07-02 重庆泰濠制药有限公司 一种硼替佐米的合成方法
CN102492021B (zh) * 2011-12-13 2013-10-23 重庆泰濠制药有限公司 硼替佐米的制备工艺
EP2793900B1 (en) * 2011-12-22 2018-08-22 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
CN103374026A (zh) * 2012-04-27 2013-10-30 重庆医药工业研究院有限责任公司 一种硼替佐米中间体的制备方法
CN103450331B (zh) * 2012-06-05 2016-05-25 山东新时代药业有限公司 一种硼替佐米的精制方法
JP2015532915A (ja) 2012-09-11 2015-11-16 シプラ・リミテッド ボルテゾミブの製造方法
WO2014072985A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
CA2891822A1 (en) 2012-11-16 2014-05-22 Shilpa Medicare Limited Crystalline bortezomib process
EP3922635A1 (en) 2012-12-07 2021-12-15 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN103897026A (zh) * 2012-12-29 2014-07-02 朱继东 硼替佐米关键中间体的晶型，制备方法及其运用
CN103897027A (zh) * 2012-12-29 2014-07-02 曹亚英 关键中间体晶型，制备方法及其在硼替佐米合成中的运用
JP6346904B2 (ja) 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
WO2014170628A1 (en) 2013-04-16 2014-10-23 Cipla Limited Process for the preparation of bortezomib mannitol ester
CN104211758B (zh) * 2013-05-29 2020-06-12 深圳翰宇药业股份有限公司 一种硼替佐米的制备方法
CN103497233B (zh) * 2013-09-30 2015-04-08 哈药集团技术中心 一种硼替佐米的制备方法
CN103554219A (zh) * 2013-10-01 2014-02-05 昆明贵研药业有限公司 一种制备硼替佐米的方法
KR101691353B1 (ko) * 2013-12-09 2016-12-30 주식회사 경보제약 보르테조밉의 제조방법 및 그의 신규 중간체
US10167311B2 (en) 2014-02-03 2019-01-01 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
AU2015264272A1 (en) 2014-05-20 2016-11-24 Millennium Pharmaceuticals, Inc. Boron-containing proteasome inhibitors for use after primary cancer therapy
EP3154989B1 (en) 2014-06-11 2021-03-24 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP6420629B2 (ja) * 2014-10-30 2018-11-07 ボーグワーナー インコーポレーテッド チェーンガイドおよびチェーンテンショナアーム
DE102015204151A1 (de) * 2015-03-09 2016-09-15 Adidas Ag Ball, insbesondere Fußball, und Verfahren zur Herstellung eines Balls
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
KR20190127681A (ko) * 2017-02-17 2019-11-13 프레세니어스 카비 온콜로지 리미티드 붕소산 에스테르의 개선된 제조방법
PH12019502037B1 (en) 2017-03-06 2024-06-05 Everest Medicines Singapore Pte Ltd Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN109305980B (zh) 2017-07-28 2022-10-11 成都奥璟生物科技有限公司 一种硼酸酯化合物、其合成方法及其用途
EP3676272A4 (en) * 2017-09-02 2021-04-21 Sun Pharmaceutical Industries Limited IXAZOMIB CITRATE PREPARATION PROCESS
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN111187336B (zh) * 2018-11-14 2022-05-20 正大天晴药业集团股份有限公司 硼替佐米的精制方法
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process
US20250059215A1 (en) 2023-08-07 2025-02-20 Tae Life Sciences Llc Trifluoroborate (BF3) Compositions For Use In Boron Neutron Capture Therapy and Methods Thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31992A (en) * 1968-05-08 1973-07-30 American Cyanamid Co Synthetic thyrocalcitonins and method of making them
ZA794723B (en) * 1978-09-11 1980-08-27 Univ Miami Anti-hypertensive agents
US4525309A (en) * 1983-03-15 1985-06-25 Washington State University Research Foundation, Inc. Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
ES8603405A1 (es) * 1985-04-22 1985-12-16 Inke Sa "procedimiento para la obtencion del ester benzilico de 1-(n-(1--etoxicarbonil-3-oxo-fenilpropil)-l-alanil)-l-prolina".
SE8506094D0 (sv) * 1985-12-20 1985-12-20 Astra Laekemedel Ab New antibacterial agents and intermediates therefor
US4701545A (en) * 1986-02-12 1987-10-20 Washington State University Research Foundation, Inc. Preparation of α,α-dihaloalkyl boronic esters
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) * 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
EP1355910B1 (en) * 2001-01-25 2011-03-09 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation of boronic acid compounds
JPWO2003033506A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
WO2003033507A1 (fr) * 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
ES2974758T3 (es) 2004-03-30 2024-07-01 Millennium Pharm Inc Síntesis de compuestos de ésteres y ácidos borónicos
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
WO2010146176A2 (en) * 2009-06-19 2010-12-23 Lek Pharmaceuticals D.D. Process for hydrogenation of halogenoalkenes without dehalogenation

Also Published As

Publication number Publication date
HUE056859T2 (hu) 2022-03-28
SG151322A1 (en) 2009-04-30
CN1960996A (zh) 2007-05-09
CN103396427B (zh) 2018-04-13
US20200157143A1 (en) 2020-05-21
RS53259B (en) 2014-08-29
NL1028639C2 (nl) 2007-01-17
RS51983B (en) 2012-02-29
US20130005968A1 (en) 2013-01-03
LT3385267T (lt) 2021-11-10
CA2560886A1 (en) 2005-10-20
IL219856A (en) 2015-05-31
HRP20140339T1 (hr) 2014-05-09
SG182998A1 (en) 2012-08-30
PL4008721T3 (pl) 2024-05-13
AR049374A1 (es) 2006-07-26
DK1756121T3 (da) 2012-01-09
SI3385267T1 (sl) 2022-04-29
IL178250A0 (en) 2006-12-31
JP2007530687A (ja) 2007-11-01
SI1756121T1 (sl) 2012-03-30
CY1115336T1 (el) 2017-01-04
SG10201600029PA (en) 2016-02-26
EP4008721B1 (en) 2024-01-03
EA200601795A1 (ru) 2007-04-27
WO2005097809A3 (en) 2006-02-16
UY28830A1 (es) 2005-09-30
HK1164320A1 (en) 2012-10-19
EP4008721A1 (en) 2022-06-08
JP2010241816A (ja) 2010-10-28
HUE065769T2 (hu) 2024-06-28
CL2014002252A1 (es) 2014-12-05
DOP2011000293A (es) 2011-12-15
TWI386212B (zh) 2013-02-21
US20220204558A1 (en) 2022-06-30
RS62738B1 (sr) 2022-01-31
TW200616646A (en) 2006-06-01
NL1033189A1 (nl) 2007-10-22
US20210395301A1 (en) 2021-12-23
HRP20212002T1 (hr) 2022-04-01
US8283467B2 (en) 2012-10-09
PT4008721T (pt) 2024-03-21
SG182999A1 (en) 2012-08-30
NL1033190A1 (nl) 2007-04-23
CL2010000350A1 (es) 2011-01-28
HK1246300A1 (zh) 2018-09-07
CA2859119A1 (en) 2005-10-20
ES2974758T3 (es) 2024-07-01
HRP20110846T1 (hr) 2011-12-31
MX367324B (es) 2019-08-15
EP1756121B1 (en) 2011-08-24
US9862745B2 (en) 2018-01-09
FI4008721T3 (fi) 2024-03-19
UY35578A (es) 2016-01-08
US20150038706A1 (en) 2015-02-05
JP6193960B2 (ja) 2017-09-06
BRPI0509587A (pt) 2007-09-25
ECSP066960A (es) 2006-12-20
CN111925385B (zh) 2023-11-21
LT4008721T (lt) 2024-03-25
US20190330270A1 (en) 2019-10-31
US20160362449A1 (en) 2016-12-15
JP2016056180A (ja) 2016-04-21
NL1033190C2 (nl) 2007-11-27
CA2738706A1 (en) 2005-10-20
EP1756121A2 (en) 2007-02-28
PE20110075A1 (es) 2011-02-17
WO2005097809A2 (en) 2005-10-20
NO344610B1 (no) 2020-02-10
JP4558039B2 (ja) 2010-10-06
CN108329337B (zh) 2021-06-25
HK1257298A1 (zh) 2019-10-18
US20190112334A1 (en) 2019-04-18
IL219853A (en) 2015-05-31
RS65253B1 (sr) 2024-03-29
PT1756121E (pt) 2011-11-30
KR100939598B1 (ko) 2010-02-01
AU2005230930B2 (en) 2011-09-29
JP5894952B2 (ja) 2016-03-30
UY34969A (es) 2015-02-27
EP3385267A1 (en) 2018-10-10
NL1028639A1 (nl) 2005-10-20
CA2853272A1 (en) 2005-10-20
CN103396427A (zh) 2013-11-20
KR20070007873A (ko) 2007-01-16
CR8653A (es) 2007-10-23
IL178250A (en) 2012-06-28
DK3385267T3 (da) 2021-11-01
NZ550522A (en) 2010-08-27
DK4008721T3 (da) 2024-03-25
MY145427A (en) 2012-02-15
PE20060162A1 (es) 2006-04-07
AR097310A2 (es) 2016-03-02
AR097309A2 (es) 2016-03-02
HRP20240307T3 (hr) 2024-05-10
US20210171574A1 (en) 2021-06-10
SI2377869T1 (sl) 2014-05-30
ATE521612T1 (de) 2011-09-15
US20100174072A1 (en) 2010-07-08
CN1960996B (zh) 2016-04-20
PT2377869E (pt) 2014-04-15
CN111925385A (zh) 2020-11-13
SG10201800972PA (en) 2018-03-28
AU2005230930A1 (en) 2005-10-20
SI4008721T1 (sl) 2024-05-31
CY1112053T1 (el) 2015-11-04
CN108329337A (zh) 2018-07-27
JP5414625B2 (ja) 2014-02-12
US7714159B2 (en) 2010-05-11
CA2738706C (en) 2014-10-14
US20180265546A1 (en) 2018-09-20
US20180044377A1 (en) 2018-02-15
US20050240047A1 (en) 2005-10-27
IL219853A0 (en) 2012-06-28
ES2457593T3 (es) 2014-04-28
EP2377868A1 (en) 2011-10-19
NZ598172A (en) 2013-08-30
EP2377869B1 (en) 2014-01-29
ZA200608689B (en) 2007-09-26
US20200369722A1 (en) 2020-11-26
IL219856A0 (en) 2012-06-28
PL1756121T3 (pl) 2012-02-29
NZ586824A (en) 2012-03-30
US10000529B2 (en) 2018-06-19
NO338905B1 (no) 2016-10-31
EP3385267B1 (en) 2021-09-29
ES2371652T3 (es) 2012-01-05
EP2377869A1 (en) 2011-10-19
DK2377869T3 (da) 2014-04-14
NL1033189C2 (nl) 2008-08-14
CA2560886C (en) 2014-08-12
ME01975B (me) 2015-05-20
NO20064893L (no) 2006-12-22
PT3385267T (pt) 2021-11-23
HK1100004A1 (en) 2007-08-31
PL2377869T3 (pl) 2014-07-31
NO343966B1 (no) 2019-07-29
NO20161350A1 (no) 2006-12-22
UA90108C2 (uk) 2010-04-12
ES2899606T3 (es) 2022-03-14
EA012927B1 (ru) 2010-02-26
NO20171939A1 (no) 2006-12-22
NO20191065A1 (no) 2006-12-22
PE20142402A1 (es) 2015-02-04
CN107474062A (zh) 2017-12-15
JP2013100378A (ja) 2013-05-23
PL3385267T3 (pl) 2022-02-14

Similar Documents

Publication Publication Date Title
CY1124753T1 (el) Συνθεση ενωσεων βορονικων εστερων και οξεων
CY1125155T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
PH12015501193A1 (en) Boronate ester compounds and pharmaceutical compositions thereof
TW200801027A (en) Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
WO2010146172A3 (en) New synthetic route for the preparation of alpha-amino boronic esters
BR112012006406A2 (pt) "processo para a fabrição de n-acilbifenil alanina"
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
AR050518A1 (es) Proceso de amonolisis para la preparacion de intermedarios para inhibidores de dpp iv
NZ600786A (en) Proteasome inhibitors and processes for their preparation, purification and use
EA201100264A1 (ru) Способы синтеза 2(s),4(s),5(s),7(s)-2,7-диалкил-4-гидрокси-5-амино-8-арил-октаноил амидов
ATE477234T1 (de) Synthese von phenolischen estern von hydroxymethylphenolen
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
CY1116739T1 (el) Μεθοδος συνθεσης και κρυσταλλικη μορφη του υδροχλωρικου 4-{3-[cis-εξαϋδροκυκλοπεντα[c]πυρρολ-2(1η)-υλ] προποξυ} βενζαμιδιου καθως και η συνδεομενη ελευθερη βαση και οι φαρμακευτικες συνθεσεις οι οποιες τις περιεχουν
EA200701686A1 (ru) Свободное основание лерканидипина
DE602007007358D1 (de) Verfahren zur synthese von 2,5-dihydroxyterephthalsäure
ATE509901T1 (de) Verfahren zur synthese von 2,5- dihydroxyterephthalsäure
DE602007013944D1 (de) Verfahren zur synthese von 2,5-dihydroxyterephthalsäure
SE0402199D0 (sv) New process I
ATE479649T1 (de) Zwischenprodukte und verfahren zur herstellung aromatischer derivate von 1-adamantan
DK2167673T3 (da) Fremgangsmåde til omdannelse af C-terminale peptidestere eller -syrer til amider under anvendelse af subtilisin i tilstedeværelsen af ammoniumsalte
UA86549C2 (en) 1-(aminomethyl)-2,2,2-trifluoroethyl phosphonic acid
UA106205C2 (ru) Соединения боронатного эфира, фармацевтическая композиция (варианты), которая содержит их, и способ их получения (варианты)
TH80510A (th) การสังเคราะห์ไซคลิคเอสเตอร์ที่มีลูอิสแอซิดเป็นสื่อกลาง